Quest Diagnostics (DGX) Projected to Post Earnings on Tuesday

Quest Diagnostics (NYSE:DGX) is expected to be releasing its Q3 2025 results before the market opens on Tuesday, October 21st. Analysts expect Quest Diagnostics to post earnings of $2.51 per share and revenue of $2.7340 billion for the quarter. Quest Diagnostics has set its FY 2025 guidance at 9.630-9.830 EPS.Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 21, 2025 at 8:30 AM ET.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.05. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%.The company had revenue of $2.76 billion for the quarter, compared to analyst estimates of $2.73 billion. During the same quarter last year, the firm posted $2.35 earnings per share. Quest Diagnostics’s revenue was up 15.2% compared to the same quarter last year. On average, analysts expect Quest Diagnostics to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Quest Diagnostics Trading Up 1.5%

NYSE:DGX opened at $189.71 on Monday. The business’s 50-day simple moving average is $182.44 and its 200-day simple moving average is $176.22. Quest Diagnostics has a fifty-two week low of $146.91 and a fifty-two week high of $191.49. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.09 and a quick ratio of 0.99. The stock has a market capitalization of $21.21 billion, a PE ratio of 22.72, a price-to-earnings-growth ratio of 2.51 and a beta of 0.56.

Quest Diagnostics Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, October 20th. Stockholders of record on Friday, October 3rd will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Friday, October 3rd. Quest Diagnostics’s dividend payout ratio is 38.32%.

Analysts Set New Price Targets

DGX has been the subject of several research analyst reports. Truist Financial set a $195.00 price target on shares of Quest Diagnostics in a report on Tuesday, October 14th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Quest Diagnostics from $160.00 to $178.00 and gave the company a “hold” rating in a report on Wednesday, July 23rd. Baird R W cut shares of Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 25th. Mizuho upped their price target on shares of Quest Diagnostics from $190.00 to $210.00 and gave the company an “outperform” rating in a report on Friday. Finally, William Blair reiterated an “outperform” rating on shares of Quest Diagnostics in a report on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.06.

Insider Activity at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 8,269 shares of the firm’s stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $167.40, for a total value of $1,384,230.60. Following the completion of the transaction, the senior vice president directly owned 10,660 shares of the company’s stock, valued at approximately $1,784,484. This trade represents a 43.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael E. Prevoznik sold 28,288 shares of the firm’s stock in a transaction on Tuesday, September 23rd. The shares were sold at an average price of $187.12, for a total value of $5,293,250.56. Following the sale, the senior vice president directly owned 38,117 shares of the company’s stock, valued at $7,132,453.04. This represents a 42.60% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,186 shares of company stock valued at $9,647,471. 8.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Quest Diagnostics

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of Quest Diagnostics by 36.3% during the 2nd quarter. Bank of America Corp DE now owns 1,599,602 shares of the medical research company’s stock worth $287,337,000 after acquiring an additional 426,399 shares during the period. Alliancebernstein L.P. grew its stake in shares of Quest Diagnostics by 5.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,241,855 shares of the medical research company’s stock worth $223,074,000 after acquiring an additional 64,283 shares during the period. 8 Knots Management LLC grew its stake in shares of Quest Diagnostics by 42.9% during the 2nd quarter. 8 Knots Management LLC now owns 176,538 shares of the medical research company’s stock worth $31,712,000 after acquiring an additional 52,983 shares during the period. Treasurer of the State of North Carolina grew its stake in shares of Quest Diagnostics by 58.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 115,977 shares of the medical research company’s stock worth $20,833,000 after acquiring an additional 42,708 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of Quest Diagnostics by 8.6% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 386,138 shares of the medical research company’s stock worth $69,447,000 after acquiring an additional 30,421 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.